Sign inJoin waitlistJoin the waitlist

BT

Brent Tierney

Assistant Clinical Professor · Creighton University School of Medicine

Credentials: · · · · ·

History

Creighton University School of Medicine
Present

Completed fellowship from Ohio State Univeristy Medical Center
2013–2016
Obstetrics and Gynecology
Creighton University School of Medicine
2009–2013
Creighton University School of Medicine
2003–2007

Research

HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer
Cancer Research · 2014 · 79 citations
Laparoscopic re-operation for failed Heller myotomy
Diseases of the Esophagus · 2006 · 58 citations
HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells
Cancer Biology & Therapy · 2012 · First of 8 authors · 38 citations

David Cohn
8 papers
AI
Atif Iqbal
4 papers · 4 as a resident
CF
Charles Filipi
4 papers
Georgia McCann
4 papers · 4 as a fellow
Eric Eisenhauer
3 papers · 1 as a fellow
Jeffrey Fowler
3 papers
KR
Kellie Rath
3 papers · 3 as a fellow
Adrian Suarez
2 papers
AC
Aine Clements
2 papers · 2 as a fellow
Floor Backes
2 papers · 2 as a fellow
Kiran Turaga
2 papers · 2 as a resident
Michael Straughn
2 papers

Clinical trials

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2022–2027